BEFORE THE INTELLECTUAL PROPERTY AND INDUSTRY SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: MAY 18, 2015 2:15 P.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

INDEX

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION	
1. CALL TO ORDER.	3
2. ROLL CALL.	3
3. CONSIDERATION OF ADOPTION OF OPTION TO	3
CONVERT A CLINICAL STAGE PROGRAM AWARD	
(PA 15-01, 15-02 AND 15-03) FROM A GRANT	
TO A LOAN	
4. PUBLIC COMMENT	NONE

1	MAY 18, 2015; 2:15 P.M.
2	
3	CHAIRMAN JUELSGAARD: WELL, I WILL CALL
4	THE MEETING TO ORDER THEN. SO THIS IS, AGAIN, A
5	MEETING OF THE INTELLECTUAL PROPERTY AND INDUSTRY
6	SUBCOMMITTEE OF THE ICOC. AND I GUESS WE SHOULD
7	START WITH THE ROLL CALL OF THOSE PRESENT. SO,
8	MARIA, ARE YOU AVAILABLE TO DO THAT?
9	MS. BONNEVILLE: I AM. STEVE JUELSGAARD.
10	CHAIRMAN JUELSGAARD: PRESENT.
11	MS. BONNEVILLE: JEFF SHEEHY.
12	MR. SHEEHY: HERE.
13	MS. BONNEVILLE: OS STEWARD. JONATHAN
14	THOMAS.
15	CHAIRMAN THOMAS: HERE.
16	MS. BONNEVILLE: JOE PANETTA.
17	MR. PANETTA: HERE.
18	MS. BONNEVILLE: ANNE-MARIE DULIEGE.
19	DR. DULIEGE: HERE.
20	MS. BONNEVILLE: SUE BRYANT.
21	DR. BRYANT: HERE.
22	MS. BONNEVILLE: GREAT.
23	CHAIRMAN JUELSGAARD: ALL RIGHT.
24	WONDERFUL. WELL, WE HAVE ONE AGENDIZED ITEM, AND
25	IT'S THE CONSIDERATION OF THE ADOPTION OF AN OPTION
	3

1	TO BE ABLE TO CONVERT CLINICAL STAGE PROGRAM AWARDS
2	FROM A GRANT TO A LOAN. THIS IS SOMETHING THAT HAS
3	BEEN IN THE WORKS FOR A LITTLE WHILE AND I THINK IS
4	A REALLY GREAT IDEA. BUT I'M GOING TO TURN THE
5	MEETING OVER TO JAMES HARRISON, WHO CAN WALK US
6	THROUGH THE PROPOSAL. AND THEN WE CAN DISCUSS IT
7	AND GO FROM THERE.
8	MR. HARRISON: THANKS, STEVE. GOOD
9	AFTERNOON, EVERYONE. WHEN OUR NEW PRESIDENT JOINED
10	THE AGENCY, HE TASKED US WITH TAKING A FRESH LOOK AT
11	MANY OF OUR PROGRAMS, INCLUDING THE LOAN
12	ADMINISTRATION POLICY.
13	AS YOU MAY RECALL, THE BOARD ESTABLISHED
14	THE LOAN PROGRAM BACK IN 2009 AFTER A LOT OF
15	CONSIDERATION AND ECONOMIC MODELING. AND AMONG THE
16	GOALS FOR THE LOAN PROGRAM WERE IN SOME WAY
17	EVERGREENING CIRM BY USING THE PROCEEDS OF LOANS TO
18	MAKE NEW RESEARCH AWARDS AND ALSO TO OFFER INDUSTRY
19	AN ALTERNATIVE TO OUR TRADITIONAL GRANT PROGRAM. AT
20	LEAST BASED ON THE ECONOMIC MODELING THAT WAS DONE
21	AT THE TIME, IT WAS ENVISIONED THAT THE LOAN PROGRAM
22	WOULD ULTIMATELY TOTAL APPROXIMATELY 500 MILLION.
23	SINCE THE ADOPTION OF THE LOAN PROGRAM
24	BACK IN 2009, WE HAVE GONE THROUGH MULTIPLE
25	ITERATIONS OF THE LOAN ADMINISTRATION POLICY AND

1	TWEAKED VIRTUALLY EVERY ASPECT OF THE LOAN PROGRAMS
2	FROM WARRANTS TO THE INTEREST RATE TO WHAT WE CALL
3	THE RISK PREMIUM TO FORGIVENESS. AND EACH OF THESE
4	CHANGES, WHILE SIGNIFICANT, HASN'T FUNDAMENTALLY
5	CHANGED THE PROGRAM ITSELF.
6	TO DATE WE HAVE ISSUED ONLY FIVE LOANS.
7	AND IN YOUR SLIDES, WE HAVE THE STATUS OF THE
8	CURRENT LOAN PROGRAM. OF THOSE FIVE LOANS, ONLY TWO
9	OF THEM ARE OUTSTANDING. WE FORGAVE TWO OF THE
10	LOANS BECAUSE THE PROJECTS WERE UNSUCCESSFUL, AND
11	ONE OF THE LOAN RECIPIENTS, GERON, REPAID CIRM THE
12	AMOUNT THAT IT HAD BEEN DISBURSED PLUS INTEREST WHEN
13	IT DECIDED TO DISCONTINUE ITS STEM CELL PROGRAM FOR
14	BUSINESS REASONS.
15	SO IT'S FAIR TO SAY, AT LEAST AS
16	ORIGINALLY ENVISIONED, THE LOAN PROGRAM HAS NOT MET
17	ALL OF THE GOALS WE SET OUT FOR IT. WE BEGAN TO
18	LOOK AT THE LOAN ADMINISTRATION POLICY ITSELF 2.0
19	SPIRIT AND ACTUALLY WENT THROUGH MULTIPLE REVISIONS
20	OF IT TO TRY TO STREAMLINE IT. I THINK ONE OF THE
21	THINGS WE FOUND WAS THAT IT WAS A VERY COMPLEX
22	PROGRAM. IT WAS HARD TO EXPLAIN TO APPLICANTS, AND
23	MANY OF THE PROVISIONS WERE CHALLENGING TO THEM. IN
24	PARTICULAR, THE WARRANT COVERAGE PROVED TO BE AN
25	OBSTACLE FOR SOME COMPANIES. THE LOAN FORGIVENESS

1	OPTION, WHILE IMPORTANT, ALSO HAD ONE SIGNIFICANT
2	CAVEAT, WHICH IS THAT IF THE PROGRAM ULTIMATELY WAS
3	RESURRECTED, THE LOAN WOULD AUTOMATICALLY BE
4	REINSTATED. AND WHAT THAT MEANT AS A PRACTICAL
5	MATTER FOR OUR LOAN RECIPIENTS IS THAT THAT LOAN,
6	EVEN IF CIRM FORGAVE IT, REMAINED ON THE COMPANY'S
7	BOOKS ESSENTIALLY IN PERPETUITY BECAUSE THERE'S
8	ALWAYS SOME CHANCE FROM AN ACCOUNTING PERSPECTIVE
9	THAT THE OBLIGATION COULD SPRING BACK TO LIFE.
10	SO THAT PROVED TO BE AN OBSTACLE AS WELL.
11	SO IN DISCUSSIONS WITH RANDY, WE BATTED AROUND
12	SEVERAL IDEAS, AND ULTIMATELY RANDY CAME UP WITH THE
13	IDEA OF INSTEAD OF OFFERING THIS STAND-ALONE LOAN
14	PROGRAM, INSTEAD OFFERING AN OPTION WHERE AN AWARDEE
15	WOULD CONVERT ITS GRANT TO A LOAN AND ESSENTIALLY
16	HAVE THE OPTION OF OVER THE COURSE OF THE PROGRAM
17	CHANGING THE STATUS OF THE AWARD.
18	WE BELIEVE THAT THIS PROPOSAL WILL HELP US
19	ACHIEVE SOME OF THE AIMS OF CIRM 2.0. SO LET ME
20	JUST WALK YOU BRIEFLY THROUGH SOME OF THE DETAILS.
21	SO REMEMBER THIS WOULD APPLY, AT LEAST FOR NOW, ONLY
22	TO CIRM'S CLINICAL STAGE PROJECT AWARDS, SO THE
23	THREE PROGRAM ANNOUNCEMENTS THAT THE BOARD APPROVED
24	AS PART OF CIRM 2.0: 15-01, 15-02, AND 15-03. AND
25	PURSUANT TO THIS POLICY, WE WOULD ALLOW THE AWARDEE

1	TO CONVERT THEIR AWARD FROM A GRANT TO A LOAN WITHIN
2	THE EARLIER OF MARKETING APPROVAL BY THE FDA OR
3	SEVEN YEARS FROM THE EFFECTIVE DATE OF THE AWARD.
4	WE WOULD REQUIRE THE AWARDEE TO REPAY CIRM WITHIN
5	TEN DAYS OF MAKING THE ELECTION TO CONVERT FROM A
6	GRANT TO A LOAN UNLESS CIRM AND THE AWARDEE AGREE TO
7	DIFFERENT TERMS. AND WE WOULD SET THE REPAYMENT
8	RATE BASED ON THE DATE OF THE REPAYMENT AND REQUIRE
9	HIGHER RATE THE LATER IN TIME THE REPAYMENT OCCURS.
10	NOW, WE HAVE NOT YET SET THAT RATE OF
11	REPAYMENT. AS YOU WILL SEE IN THE DRAFT POLICY, WE
12	LEFT THAT BLANK. WE ARE IN THE PROCESS OF
13	CONSULTING WITH AN EXPERT TO GET SOME ADVICE ON WHAT
14	THE APPROPRIATE RATE WOULD BE FROM AN ECONOMIC AND
15	FINANCIAL PERSPECTIVE, AND WE WILL COME BACK TO YOU
16	ONCE WE'VE DONE THAT DUE DILIGENCE.
17	IMPORTANTLY, THE CONVERSION FROM A GRANT
18	TO A LOAN WOULD BECOME FINAL ONLY AFTER THE AWARDEE
19	HAS SATISFIED THE TERMS OF THE CONVERSION, MEANING
20	FULL REPAYMENT TO CIRM. AND CIRM'S ACCESS, PRICING,
21	AND MARCH-IN REGULATIONS, WHICH ARE PART OF OUR IP
22	RULES, WOULD CONTINUE TO APPLY TO AN AWARDEE THAT
23	CONVERTED ITS AWARD FROM A GRANT TO A LOAN.
24	WE THINK THAT THIS OPTION WILL HELP
25	ADVANCE CIRM'S MISSION TO ACCELERATE THE DELIVERY OF
	7

1	STEM CELL THERAPIES TO PATIENTS WITH UNMET MEDICAL
2	NEEDS IN THREE WAYS. ONE, AS WITH THE ORIGINAL LOAN
3	PROGRAM, THIS IS DESIGNED TO ATTRACT INDUSTRY
4	INVOLVEMENT, BUT WE THINK THAT THIS HAS SEVERAL
5	ADVANTAGES TO THE EXISTING PROGRAM. IT'S
6	STREAMLINED, IT'S CLEANER, IT AVOIDS THE HANGING
7	OBLIGATION THAT I REFERENCED EARLIER WHEREBY AN
8	AWARDEE WHO HAS A LOAN THAT'S FORGIVEN CONTINUES TO
9	SHOW THAT AS AN OBLIGATION ON ITS BOOKS INTO
10	PERPETUITY. WE THINK IT ALSO CREATES AN INCENTIVE
11	FOR THE AWARDEES TO REPAY CIRM EARLIER BECAUSE THE
12	EARLIER YOU REPAY, THE LESS YOU WOULD HAVE TO REPAY
13	CIRM. AND WE COULD THEN USE THOSE PROCEEDS TO MAKE
14	NEW RESEARCH AWARDS. AND IT ALSO INCREASES
15	EFFICIENCY SIGNIFICANTLY, ELIMINATING A LOT OF THE
16	COMPLEXITY OF THE STAND-ALONE LOAN ADMINISTRATION
17	POLICY, REDUCING THE BURDEN OF HAVING TO NEGOTIATE
18	EACH LOAN AWARD SEPARATELY, AND THE TIME AND EFFORT
19	OF ENFORCING A SEPARATE ADMINISTRATIVE POLICY
20	COVERING LOANS.
21	SO WE BELIEVE THAT THIS WILL BE AN
22	IMPORTANT ENHANCEMENT TO THE OPTIONS THAT WE
23	CURRENTLY OFFER, AND WE ASK FOR THE SUBCOMMITTEE'S
24	CONSIDERATION OF IT. I'D BE HAPPY TO ANSWER ANY
25	QUESTIONS.

1	CHAIRMAN JUELSGAARD: ARE THERE ANY
2	QUESTIONS OF ANY MEMBERS OF THE SUBCOMMITTEE?
3	MR. PANETTA: STEVE, THIS IS JOE. I HAVE
4	A QUESTION THAT'S PROBABLY COMPLETELY NAIVE, BUT IF
5	YOU'LL LET ME ASK IT.
6	CHAIRMAN JUELSGAARD: SURE.
7	MR. PANETTA: THANK YOU VERY MUCH. I
8	GUESS WHERE I'M CONFUSED ON THIS IS WHAT IS THE
9	INCENTIVE FOR A COMPANY TO CONVERT A GRANT TO A LOAN
10	IF A GRANT DOES NOT REQUIRE REPAYMENT AND A LOAN
11	DOES?
12	MR. HARRISON: GRANTS COME WITH REVENUE
13	SHARING TERMS, ROYALTIES ESSENTIALLY, .1 PERCENT PER
14	ONE MILLION OF CIRM AWARD.
15	MR. PANETTA: OKAY. SO THE LOAN COULD
16	CONCEIVABLY COST THE COMPANY LESS THAN THE REVENUE
17	SHARING ROYALTY?
18	MR. HARRISON: YEAH. THE COMPANY WOULD
19	HAVE TO DO ITS OWN ECONOMIC ANALYSIS AND SORT THAT
20	OUT, BUT IT DOES PROVIDE AN ALTERNATIVE TO OUR
21	CURRENT OFFERINGS.
22	MR. PANETTA: OKAY.
23	DR. MILLS: BASICALLY, JOE, IT'S SIMILAR
24	TO A ROYALTY BUYOUT PROVISION THAT SOMETIMES EXISTS.
25	WHAT WE FOUND IS THAT ROYALTY ENTANGLEMENTS ALMOST,
	0
	9

1	IRRESPECTIVE OF THEIR SIZE, ARE DETRIMENTAL TO
2	GETTING PARTNERSHIPS DONE. AND SO EVEN IF IT'S MORE
3	EXPENSIVE, OFTENTIMES LICENSING COMPANIES WOULD
4	RATHER TO BE ABLE TO JUST BUY OUT THE ENTANGLEMENT
5	IN ITS ENTIRETY AND NOT HAVE TO WORRY ABOUT
6	DOWNSTREAM PROVISIONS.
7	MR. PANETTA: GREAT. THANKS A LOT. THAT
8	HELPS ME A LOT. I APPRECIATE IT.
9	CHAIRMAN THOMAS: DO WE WANT TO PROVIDE
10	FOR A ROYALTY BUYOUT OPTION ON TOP OF THIS BECAUSE
11	THERE ARE FIRMS OUT THERE THAT ARE DOING THAT?
12	DR. MILLS: I THINK THE WAY THAT THIS WAS
13	CONSTRUCTED SUFFICIENTLY ADDRESSES THAT NEED. AND
14	IT DOES IT IN A WAY, AND JAMES CAN TALK MORE ABOUT
15	IT, THAT FALLS WITHIN APPROPRIATE CONSTRUCTS FOR
16	WHAT THE STATE OF CALIFORNIA CAN DO. THE IDEA OF
17	ROYALTY BUYOUT WAS ONE OF THE THINGS WE TALKED
18	ABOUT, BUT I THINK THIS MECHANISM MAY DO IT BETTER.
19	CHAIRMAN JUELSGAARD: IT IS THE EQUIVALENT
20	OF A ROYALTY BUYOUT, AS YOU SAID EARLIER, RANDY. IN
21	ESSENCE, WHAT SOMEBODY WILL DO AT THE APPROPRIATE
22	TIME IS LOOK AT THE COST OF ROYALTY VERSUS THE COST
23	OF A BUY-DOWN AND MAKE A DECISION ON WHICH THEY'D
24	RATHER TAKE THE CHANCE ON. SO IT EFFECTIVELY, IN MY
25	EYES, EVEN THOUGH WE CALL IT A LOAN, IT'S A ROYALTY
	10

1	BUYOUT PROVISION.
2	I DO HAVE ONE QUESTION, AND THAT GOES TO
3	TIMING. SO THIS WEEK WE'RE MEETING, WE HAVE A BOARD
4	MEETING, RIGHT, AND WE'RE GOING TO CONSIDER
5	APPLICATIONS IN RESPONSE TO 15-01 AND 15-02
6	APPLICATIONS. AND SO WE WON'T HAVE COMPLETED THIS
7	YET. WE'RE GOING TO GO TO THE BOARD AND WE'RE GOING
8	TO SAY WE WOULD LIKE YOU TO ADOPT THIS, TO DELEGATE
9	AUTHORITY FOR SETTING THE EXACT TIERING OF THE
10	REPAYMENTS, BACK TO THE SUBCOMMITTEE BECAUSE WE'RE
11	CONSULTING WITH SOME PEOPLE WHO ARE GOING TO HELP US
12	FIGURE OUT WHAT WE THINK IS APPROPRIATE. AND THEN I
13	THOUGHT I SAW A PROVISION THAT WE WOULD GO BACK TO
14	THE BOARD WITH WHAT THE DETERMINATION OF THAT WAS.
15	MR. HARRISON: STEVE, I THINK I CAN CLEAR
16	UP THAT CONFUSION. WHAT WE WOULD REQUEST IS THAT
17	THE SUBCOMMITTEE RECOMMEND APPROVAL OF ADOPTION TO
18	THE BOARD AND ASK THE BOARD TO DELEGATE TO THE
19	SUBCOMMITTEE THE AUTHORITY TO SET THE RATE OF
20	RETURN. BECAUSE THIS IS BEING ADOPTED AS AN INTERIM
21	REGULATION, IT WOULD GO INTO EFFECT IMMEDIATELY.
22	BUT ULTIMATELY, AS WITH THE REMAINDER OF THE GRANTS
23	ADMINISTRATION POLICY FOR 2.0 AWARDS, IT WILL GO
24	THROUGH THE ADMINISTRATIVE PROCEDURE ACT. SO
25	ULTIMATELY WILL COME BACK TO THE BOARD FOR FINAL

1	ADOPTION.
2	SO THAT WAS THE REFERENCE TO GOING BACK TO
3	THE BOARD, BUT THAT WOULDN'T IMPEDE THE RULE FROM
4	TAKING EFFECT ONCE WE GET SUFFICIENT INFORMATION TO
5	RECOMMEND AN APPROPRIATE RATE OF RETURN AND COME
6	BACK TO THIS SUBCOMMITTEE FOR APPROVAL.
7	CHAIRMAN JUELSGAARD: SO LET ME JUST ASK
8	ABOUT THAT. SO IT'S THAT SECOND STEP THAT'S GOING
9	BACK TO THE BOARD FOR FINALIZATION. SO LET'S ASSUME
10	THAT THIS PROCEEDS THIS SUBCOMMITTEE IS DELEGATED
11	THE AUTHORITY TO DEVELOP THE TIERS THAT ARE GOING TO
12	BE USED IN TERMS OF REPAYMENT. AND SO NOW THAT'S
13	DONE AND PEOPLE ARE GRANTED THE FUNDS TO DO
14	PROJECTS, AND WE GET TO THE FINALIZATION STAGE AND
15	THEY'RE FAR DOWN THE ROAD, BUT SOMEWHERE DOWN THE
16	ROAD GOING TO THE BOARD AND THE BOARD SAYS, WELL, WE
17	REALLY DON'T LIKE THE TIERING THAT YOU DID. WE
18	THINK IT'S EITHER TOO HIGH, TOO LOW, OR SOMETHING
19	ELSE. BUT WE'VE ALREADY BEEN OUT THERE, IN ESSENCE,
20	WITH THIS PROGRAM IN PLACE. SO IS THERE A RISK THAT
21	THE BOARD COULD, IN ESSENCE, UNDO WHAT WE WOULD WANT
22	TO HAVE DONE IN THE MEANTIME?
23	MR. HARRISON: NO. BECAUSE ANY CHANGES
24	MADE BY THE BOARD AT THAT POINT IN TIME WOULD APPLY
25	PROSPECTIVELY ONLY.

1	CHAIRMAN JUELSGAARD: OKAY.
2	MR. HARRISON: SO AWARDS MADE UNDER THE
3	INTERIM RULE, WHICH WOULD HAVE FULL FORCE AND EFFECT
4	UNTIL FINAL ADOPTION, WOULD REMAIN IN EFFECT FOR
5	WHATEVER AWARDS ARE COVERED.
6	CHAIRMAN JUELSGAARD: OKAY. GREAT.
7	PERFECT.
8	HOW LONG WILL IT TAKE BEFORE WE GET TO THE
9	POINT OF BEING FINALIZED BY THE BOARD?
10	MR. HARRISON: PROBABLY ABOUT SIX MONTHS.
11	CHAIRMAN JUELSGAARD: OKAY. GOT IT. THAT
12	ANSWERS MY QUESTIONS.
13	MR. HARRISON: THAT'S JUST A CONSEQUENCE
14	OF THE TIME IT TAKES TO GO THROUGH THE PUBLIC
15	HEARINGS AND PUBLIC COMMENT UNDER THE ADMINISTRATIVE
16	PROCEDURE ACT.
17	CHAIRMAN JUELSGAARD: WHEN DO WE EXPECT
18	THAT WE WILL HAVE FEEDBACK FROM A CONSULTANT AS TO
19	WHAT THEY THINK THE APPROPRIATE TIERING SHOULD BE?
20	MR. HARRISON: WE WOULD HOPE TO HAVE THAT
21	FEEDBACK WITHIN THE NEXT COUPLE OF WEEKS.
22	CHAIRMAN JUELSGAARD: OKAY.
23	MR. HARRISON: SO WE WILL TRY TO SCHEDULE
24	ANOTHER MEETING OF THE SUBCOMMITTEE PERHAPS A MONTH
25	FROM NOW.

1	CHAIRMAN JUELSGAARD: BUT WHATEVER
2	DECISION GETS MADE A MONTH FROM NOW, LET'S SAY, IS
3	GOING TO BE APPLICABLE TO WHATEVER GRANTS ARE MADE
4	THIS WEEK; IS THAT RIGHT?
5	MR. HARRISON: YES.
6	CHAIRMAN JUELSGAARD: AND AS FAR AS GRANTS
7	THAT HAVE ALREADY BEEN MADE, TO THE TWO THAT ARE
8	STILL OUTSTANDING, WHAT DO WE INTEND IN THAT REGARD?
9	MR. HARRISON: THIS NEW OPTION WOULD HAVE
10	NO EFFECT ON THOSE AWARDEES.
11	I DID RAISE ONE ISSUE EARLIER, WHICH WE
12	MAY WANT TO RECONSIDER FOR THOSE EXISTING PROGRAMS,
13	AND THAT IS THE FACT THAT UNDER OUR CURRENT LOAN
14	ADMINISTRATION POLICY, IF CIRM FORGIVES A LOAN, IT
15	NONETHELESS REMAINS ON THE COMPANY'S BOOKS BECAUSE
16	WE HAVE A TERM IN THE CURRENT LOAN ADMINISTRATION
17	POLICY WHICH PROVIDES THAT THE OBLIGATION SPRINGS
18	BACK TO LIFE IF THE COMPANY SHOULD EVER RESTART
19	THEIR RESEARCH PROGRAM. AND THAT CARRIES BOTH A
20	REPAYMENT OBLIGATION AND INTEREST AT A RATE TO BE
21	SET BY THE SUBCOMMITTEE NOT HIGHER THAN WHATEVER
22	LIBOR IS AT THAT POINT IN TIME PLUS 2 PERCENT. SO
23	WE MAY WANT TO REVISIT THAT POLICY. WE KNOW IT HAS
24	CAUSED SOME CHALLENGES.
25	CHAIRMAN JUELSGAARD: NO, I UNDERSTAND.

1	SO ONE OF THE SIMPLE FIXES FOR THAT ISSUE IS TO JUST
2	SIMPLY CONVERT THAT GRANT THAT WAS MADE AS A LOAN AT
3	THAT TIME INTO A REGULAR GRANT WITH THIS LOAN OPTION
4	PROVISION ASSOCIATED WITH IT. IN OTHER WORDS, TO
5	GRANT THAT PARTICULAR COMPANY IN.
6	MR. HARRISON: YEAH. WE HAVE BEEN
7	INTERNALLY DISCUSSING SOME OF THOSE OPTIONS, STEVE.
8	AND WE WILL COME BACK TO THE SUBCOMMITTEE WITH SOME
9	IDEAS.
10	CHAIRMAN JUELSGAARD: OKAY. GREAT. ARE
11	THERE ANY OTHER QUESTIONS OR DISCUSSION?
12	MR. SHEEHY: YES. I HAVE A QUESTION,
13	STEVE. THIS IS JEFF SHEEHY.
14	CHAIRMAN JUELSGAARD: YEAH, JEFF. GO
15	AHEAD.
16	MR. SHEEHY: SO I HAD NOT REALIZED THIS
17	THAT WAS A ROYALTY BUYOUT PROGRAM. SO WHO RECEIVES
18	THE ROYALTIES?
19	MR. HARRISON: SO I'M NOT SURE I WOULD
20	CALL IT A ROYALTY BUYOUT.
21	MR. SHEEHY: HE SAID IT WAS A ROYALTY
22	BUYOUT.
23	MR. HARRISON: SO LET ME TAKE A STEP BACK.
24	WE HAVE AN EXISTING LOAN PROGRAM WHICH IS AUTHORIZED
25	UNDER PROP 71. UNDER THAT PROGRAM AND UNDER OUR

1	GOVERNING LAW, THE PROCEEDS OF LOANS COME BACK TO
2	CIRM. AND THAT'S ALWAYS BEEN THE CASE SINCE DAY ONE
3	OF OUR EXISTING LOAN PROGRAM. WHAT WE'RE REALLY
4	TRYING TO DO IS ELIMINATE SOME OF THE ADMINISTRATIVE
5	COMPLEXITY OF OUR EXISTING LOAN PROGRAM BY GIVING
6	AWARDEES AN OPTION FOR THESE THREE PROGRAMS TO
7	CONVERT THEIR AWARD FROM A GRANT TO A LOAN WITHIN A
8	SPECIFIED PERIOD OF TIME AND TO REPAY CIRM, AS THEY
9	WOULD WITH A LOAN, NOT A GRANT, WITH AN INTEREST
10	RATE THAT ESCALATES DEPENDING UPON THE DATE OF
11	REPAYMENT. SO THE EARLIER THEY REPAY US, THE LESS
12	THEY PAY. THE LATER THEY PAY, THE MORE THEY PAY.
13	MR. SHEEHY: BUT ROYALTIES THAT ARE DUE
14	UNDER A GRANT PROGRAM, THOSE GO TO THE STATE OF
15	CALIFORNIA TO THE GENERAL FUND.
16	MR. HARRISON: THAT'S CORRECT.
17	MR. SHEEHY: SO WITH A ROYALTY BUYOUT,
18	WE'RE ACTUALLY DIVERTING MONEY FROM THE GENERAL FUND
19	BACK INTO CIRM.
20	DR. MILLS: SO NOT NECESSARILY BECAUSE THE
21	WAY WE STRUCTURED SO WE HAVE A LOAN PROGRAM THAT
22	DOES EXACTLY THAT. SO IF WE WERE MODIFYING OUR LOAN
23	PROGRAM TO MAKE IT BETTER, TO MAKE IT MORE USER
24	FRIENDLY, THEN YOU COULD ASSUME THAT PEOPLE WOULD
25	SELECT THE LOAN PROGRAM. WE WOULD ISSUE LOANS.
	10

1	THOSE LOANS WOULD BE REPAID TO US. CIRM WOULD THEN
2	TAKE THAT MONEY, REINVEST IT INTO OTHER THINGS WHERE
3	THE LOAN PROGRAM (INAUDIBLE), BUT THE GRANT AND
4	ROYALTY PROVISION RECYCLED WAS DONE, THEN THE STATE
5	OF CALIFORNIA WOULD GET REPAID. BUT THE STATE OF
6	CALIFORNIA ISN'T LOSING OUT ON THAT MONEY. IT'S
7	COMING BACK TO CIRM, NOT TO BE EVAPORATED, BUT TO BE
8	REINVESTED IN THINGS THAT HAVE FUTURE ROYALTY
9	GENERATING OPPORTUNITIES.
10	MR. SHEEHY: I APOLOGIZE FOR BEING
11	DIFFICULT, BUT PART OF THE COMMITMENT OF PROP 71 WAS
12	TO RETURN MONEY TO THE GENERAL FUND, AND THIS IS ONE
13	OF THE KEY WAYS. AND I GUESS I HAD NOT THOUGHT OF
14	THIS AS A ROYALTY BUYOUT PROGRAM. I HAD THOUGHT OF
15	IT AS SUBSTITUTION FOR A CURRENT LOAN PROGRAM. AT
16	LEAST THE INDUSTRY PEOPLE CLEARLY SEE THIS AS A
17	ROYALTY BUYOUT PROGRAM, AND I DON'T KNOW THAT I FEEL
18	COMFORTABLE IN TAKING ACTION TO BUY OUT ROYALTIES
19	THAT WOULD BE DUE TO THE GENERAL FUND TO REPAY THE
20	BONDS THAT WERE ISSUED AND THE INTEREST THAT WAS
21	ISSUED ON THOSE BONDS THAT IS BEING PAID ON THOSE
22	BONDS.
23	CHAIRMAN JUELSGAARD: JEFF, I'M SORRY IF I
24	ADDED TO THE CONFUSION. SO I THINK YOU HAVE TO
25	DIVORCE WHAT IS ACTUALLY HAPPENING FROM THE

PERSPECTIVE THAT IS ASSOCIATED WITH THIS. BUT TO GO
BACK TO WHAT I SAID, I DO THINK THAT FROM THE
PERSPECTIVE OF SOMEBODY IN INDUSTRY, WHEN THEY WOULD
LOOK AT THIS AND THINK ABOUT WHAT TO DO, DO I
CONVERT THIS INTO A LOAN OR DO I JUST SIMPLY STAY
WITH THE EXISTING GRANT AND THE ROYALTY OBLIGATIONS
THAT GO WITH IT, IT IS VERY MUCH IN MY MIND, IF I'M
ON THE INDUSTRY SIDE, TANTAMOUNT TO LOOKING AT
BUYING OUT MY ROYALTY STREAM, WHICH IN THE
VERNACULAR IS CALLED A ROYALTY BUY-DOWN OR BUYOUT.
SO WHILE LEGALLY IT'S SET UP AS A LOAN,
SOME PEOPLE MIGHT WELL HAVE THE VIEW THAT IT WAS A
WAY OF ELIMINATING ROYALTIES WITH CREATING A
CERTAINTY OF A PAYMENT THAT'S TO BE MADE.
SO IF THAT'S A CONCERN OF YOURS, IT'S NOT
THE LEGAL ISSUE. IT'S THE PERSPECTIVE ISSUE.
CHAIRMAN THOMAS: IF SOMEBODY EXERCISES
OPTION, WHAT IF YOU HAD A CERTAIN PERCENTAGE THAT
WOULD HAVE CORRESPONDED TO WHAT THE STATE MIGHT BE
GETTING BACK UNDER THE ROYALTY STREAM GO TO THE
STATE AND THE BALANCE GO BACK TO CIRM?
CHAIRMAN JUELSGAARD: WELL, WE WOULDN'T
KNOW WHAT THE STATE WOULD BE RECEIVING IN TERMS OF A
ROYALTY, RIGHT? IS THAT WHAT YOU'RE SAYING, J.T.?
I'M SORRY.

1	CHAIRMAN THOMAS: I'M TRYING TO FIGURE OUT
2	HOW YOU CAN PLACE I UNDERSTAND WHAT JEFF IS
3	SAYING.
4	CHAIRMAN JUELSGAARD: I JUST DON'T KNOW
5	HOW YOU CAN DIVINE WHAT'S WHAT. I MEAN, YOU KNOW,
6	PAYING A LUMP SUM IS VERY STRAIGHTFORWARD. YOU KNOW
7	EXACTLY WHAT YOU ARE GETTING. TRYING TO FIGURE OUT
8	IF SOME OF THAT MONEY IS PARTIALLY ONE THING AND
9	ANOTHER I THINK IS NIGH NEAR IMPOSSIBLE.
10	IS THERE FURTHER DISCUSSION?
11	DR. DULIEGE: THIS IS ANNE-MARIE. FOR ME
12	IT WAS PRETTY CLEAR. I KNOW THE CHANGES THAT ARE
13	BEING MADE IS VERY MUCH STILL WITHIN THE INTENT OF
14	THE GRANTS, AND SO I'M COMFORTABLE WITH IT.
15	CHAIRMAN JUELSGAARD: ALL RIGHT. OTHERS?
16	DR. BRYANT: I'M COMFORTABLE WITH WHAT
17	I'VE BEEN LISTENING TO. I THINK THIS IS A WISE MOVE
18	AT THIS STAGE OF THE GAME.
19	MR. PANETTA: I JUST WANT TO GIVE YOU MY
20	PERSPECTIVE ON THIS BUYOUT, THE APPEARANCE OF A
21	BUYOUT. FROM MY STANDPOINT, IT'S A TRADE-OFF IN THE
22	SENSE THAT THE LOAN IN A WAY PROVIDES CIRM WITH THE
23	ASSURANCE THAT THE DOLLARS ARE GOING TO BE PAID
24	BACK; WHEREAS, THE GRANT KIND OF ASSUMES THAT IF
25	THERE'S SUCCESS, THE DOLLARS WILL BE PAID BACK, BUT

1	THERE ISN'T THE ASSURANCE THERE. SO I THINK IT'S
2	KIND OF A TRADE-OFF IN WHETHER IT'S A ROYALTY BUYOUT
3	OR NOT. LEGALLY THAT'S NOT A LEVEL OF EXPERTISE.
4	TO ME IT'S KIND OF A TRADE-OFF ON RISK DECISION THAT
5	THE COMPANY MAKES TOO.
6	MR. SHEEHY: I WOULD NOTE THAT ONE OF THE
7	TRIGGERS FOR THIS IS MARKETING APPROVAL BY THE FDA.
8	SO THAT INDICATES THAT A REVENUE STREAM IS
9	ANTICIPATED THAT WOULD BE GOING TO THE GENERAL FUND.
10	THAT IS A TRIGGER TO NOT ALLOW THIS TO HAPPEN.
11	MR. HARRISON: THE EARLIER OF SEVEN YEARS
12	OR MARKETING APPROVAL BY THE FDA.
13	DR. MILLS: THAT KIND OF PROVISION IS IN
14	THERE. SO IF YOU'RE ALREADY PAYING OR YOU'RE
15	IMMINENTLY GOING TO PAY ROYALTIES, YOU CAN'T DO IT
16	THEN. YOU HAVE TO DO IT WHEN THERE'S BASICALLY
17	RISK. YOU HAVE NO CHANCE OF GETTING READY, THERE'S
18	A PROBABILITY THAT AT LEAST EXISTS THAT ZERO MIGHT
19	BE THE FOREVER ROYALTY REPAYMENT.
20	CHAIRMAN JUELSGAARD: WELL, SO FDA
21	APPROVAL WAS THE THING THAT'S BEEN PLUGGED IN THERE.
22	THIS IS AN APPEARANCES ISSUE, AND WE'RE GETTING
23	CLOSER TO THE POINT OF REVENUE REALIZATION.
24	IRRESPECTIVE OF WHAT PEOPLE MIGHT THINK THE AMOUNT
25	OF REVENUE MIGHT BE, YOU MIGHT, INSTEAD, BACK UP THE
	20

1	REPAYMENT OBLIGATION TO THE POINT OF SUBMISSION OF A
2	BLA OR NDA OR WHATEVER THIS GOES UNDER TO THE FDA.
3	SO THE SUBMISSION OF AN APPLICATION FOR APPROVAL OF
4	THE PRODUCT TO THE FDA DRIVES. SO IT'S NOT THE
5	APPROVAL ITSELF, BUT THE SUBMISSION. APPROVALS TEND
6	TO BE 18 MONTHS OUT DEPENDING ON HOW LONG THE FDA IS
7	GOING TO TAKE TO REVIEW THESE THINGS. SO THERE
8	WOULD STILL BE UNCERTAINTY OF FDA APPROVAL AT THAT
9	POINT.
10	IS THERE ANY REACTION TO THAT AS A
11	THOUGHT?
12	MR. SHEEHY: ALL I CAN SAY
13	CHAIRMAN JUELSGAARD: NEGATIVE, POSITIVE,
14	I DON'T CARE.
15	MR. SHEEHY: STEVE, I THINK I'M GOING TO
16	BE AN OUTLIER ON THIS ONE. I HAD NOT HEARD THE TERM
17	"ROYALTY BUYOUT." AND GIVEN THE TWO DIFFERENT
18	DIRECTIONS THAT GIVEN THE TWO DIFFERENT
19	DIRECTIONS THAT INCOME FROM CIRM'S OUTLAYS CAN GO,
20	ONE IS IF IT'S A GRANT, IT RETURNS TO THE GENERAL
21	FUND OF THE STATE OF CALIFORNIA. AND THE OTHER, IF
22	IT'S A LOAN, IT'S RETURNED TO CIRM. IT FEELS LIKE
23	ROYALTY BUYOUT, AND THAT IS NOT SOMETHING I'M
24	COMFORTABLE WITH. I MEAN WALKS LIKE A DUCK, IT
25	SOUNDS LIKE A DUCK, I THINK IT'S A DUCK.

1	DR. MILLS: CAN I TRY IT ONE MORE TIME?
2	BECAUSE I THINK IT HAS TO DO WITH THE DESTINATIONS
3	OF THE MONIES THAT MATTERS HERE. AND SO WHEN WE
4	INVEST MONEY INTO A PROGRAM, THAT MONEY THE MONEY
5	THAT COMES BACK TO US HAS RIGHT NOW TWO POTENTIAL
6	DESTINATIONS. ONE OF THEM IS TO THE STATE GENERAL
7	FUND. THAT IS A TERMINAL DESTINATION, RIGHT? WHEN
8	THAT MONEY GOES BACK TO THE STATE'S GENERAL FUND, IT
9	ENDS THERE. IT DOESN'T COME BACK TO US. THERE'S NO
10	RECYCLING. THE OTHER DESTINATION IS EITHER UNDER
11	THE LOAN PROGRAM OR AS PROPOSED HERE IS A RECYCLING
12	VERSION. AND THAT IS THAT MONEY COMES BACK. IT
13	DOESN'T COME INTO THE ADMINISTRATIVE BUCKET TO GET
14	USED UP BY EXPENSES AND SALARIES AND THINGS LIKE
15	THAT. IT JUST GETS RECYCLED INTO THE SEND IT BACK
16	OUT AGAIN FOR DOING WORK BUCKET.
17	AND SO I THINK THAT DISTINCTION IS WE'RE
18	NOT DIVERTING THEM WE'RE NOT DIVERTING THE MONEY
19	FROM ONE TERMINAL DESTINATION TO ANOTHER TERMINAL
20	DESTINATION. WE'RE TAKING MONEY AND EITHER IT GOES
21	TO A TERMINAL DESTINATION OR IT COMES BACK AND GETS
22	RECYCLED TO ACCOMPLISH CIRM'S MISSION AGAIN. HOW
23	ABOUT THAT? IT'S A RECYCLING ARGUMENT IN CALIFORNIA
24	THAT WORKS LIKE
25	CHAIRMAN JUELSGAARD: LET ME ADDRESS THAT
	22

1	I AGREE WITH YOU. SO, JEFF, IT SEEMS TO ME THAT WE
2	HAVE TWO DIFFERENT OBLIGATIONS AS A BODY. ONE IS TO
3	TRY AND ADVANCE OUR STEM CELL RESEARCH AND
4	DEVELOPMENT TO GET THERAPEUTIC PRODUCTS THAT WILL DO
5	GOOD FOR PEOPLE. RIGHT? THEN THE OTHER ONE IS TO
6	TRY AND MAKE MONEY FOR THE STATE. NOW, YOU KNOW,
7	SOMETIMES THOSE THINGS ARE GOING TO BE IN OPPOSITION
8	TO EACH OTHER. SOMETIMES WE'RE GOING TO DO
9	THINGS I THINK WE PROBABLY MAKE DECISIONS ALL THE
10	TIME WHERE THE ODDS ARE A RETURN TO THE STATE MIGHT
11	BE REALLY LOW BECAUSE THE HURDLE IS SO HIGH TO GET
12	OVER WITH RESPECT TO THE DISEASE WE'RE TALKING
13	ABOUT, THAT THERE'S MORE LIKELY TO BE FAILURE THAN
14	SUCCESS, BUT WE MAKE THOSE DECISIONS BECAUSE WE
15	THINK THAT THE FIRST PURPOSE, THE ONE WHERE WE
16	INVEST MONEY TO TRY AND USE THIS AREA OF THERAPY FOR
17	THE BETTERMENT OF THE CITIZENS OF THE STATE OF
18	CALIFORNIA, THAT THAT'S A HIGHER PURPOSE THAN
19	CYCLING MONEY TO THE STATE FUNDS.
20	SO I DO THINK THAT THEY DON'T ALWAYS
21	OPERATE TOGETHER. THEY SOMETIMES OPERATE IN
22	CONFLICT, AND THAT THIS MAY BE ONE OF THEM. BUT
23	THAT'S ALL RIGHT FROM MY POINT OF VIEW BECAUSE IT'S
24	HAVING TO CHOOSE BETWEEN THE TWO, TRYING TO IMPROVE
25	HUMAN HEALTH VERSUS RETURNING MONEY TO THE STATE

1	COFFERS. IF I'M FORCED TO CHOOSE BETWEEN THOSE TWO,
2	I'M MORE LIKELY TO COME DOWN ON THE FORMER THAN ON
3	THE LATTER.
4	DR. MILLS: OR THE RECYCLING ARGUMENT.
5	CHAIRMAN JUELSGAARD: OTHER COMMENTS,
6	OTHER DISCUSSION? ACTUALLY THIS HAS BEEN A GREAT
7	DISCUSSION. JEFF, I APPRECIATE YOU'RE RAISING YOUR
8	CONCERNS ABOUT THIS. DON'T MEAN TO PUT THEM DOWN AT
9	ALL. THEY'RE VERY REAL.
10	CHAIRMAN THOMAS: STEVE, I JUST WANT TO
11	ASK JAMES A QUESTION. WHAT WERE THE PROVISIONS OF
12	PROP 71 WITH RESPECT TO LOANS IN THE FIRST INSTANCE?
13	THE REASON I'M ASKING IS OBVIOUSLY PROP 71
14	CONTEMPLATED ONE SET OF FACTS THAT WOULD HAVE MONEY
15	COMING BACK TO CIRM AS OPPOSED TO SAYING WE WANT
16	EVERYTHING TO RESULT IN MONEY GOING DIRECTLY TO THE
17	STATE. SO THERE WAS A PROVISION IN THERE. SO WHAT
18	EXACTLY, JUST FOR OUR BENEFIT HERE, DID IT SAY?
19	MR. HARRISON: PROP 71 AUTHORIZED CIRM TO
20	MAKE GRANTS OR LOANS AND REQUIRES THE BOARD TO
21	ESTABLISH POLICIES FOR GRANTS THAT BALANCE THE STATE
22	OPPORTUNITY FOR A RETURN ON ITS INVESTMENT WITH THE
23	NEED TO ENSURE THAT THE MEDICAL RESEARCH AND
24	COMMERCIALIZATION IS NOT UNNECESSARILY HINDERED.
25	WITH RESPECT TO THE LOANS, IT INCLUDES A PROVISION

1	THAT SPECIFIES THAT THE PROCEEDS OF LOANS, INCLUDING
2	PRINCIPAL AND INTEREST, GET REPAID TO CIRM FOR USES,
3	AS RANDY SAID, IN MAKING NEW RESEARCH AWARDS. SO
4	THAT MONEY BY STATUTE CANNOT BE USED TO PAY CIRM'S
5	ADMINISTRATIVE COSTS. IT HAS TO BE USED TO MAKE NEW
6	RESEARCH AWARDS. AND THAT'S THE SUM TOTAL OF WHAT
7	PROP 71 SAYS WITH RESPECT TO LOANS.
8	CHAIRMAN JUELSGAARD: ALL RIGHT. ANY MORE
9	COMMENTS, DISCUSSION, ETC., FROM THE MEMBERS OF THE
10	SUBCOMMITTEE?
11	MR. SHEEHY: WELL, DO WE WANT TO TRY TO
12	FIGURE A WAY OFF THIS CLIFF?
13	CHAIRMAN JUELSGAARD: IT DEPENDS ON IF YOU
14	THINK WE'RE ON A CLIFF.
15	MR. SHEEHY: I HAVE TO SAY THIS ISN'T
16	SOMETHING THAT I CAN SUPPORT.
17	CHAIRMAN JUELSGAARD: I UNDERSTAND THAT,
18	JEFF. I GOT THAT.
19	MR. SHEEHY: BUT IT MAY JUST BE A QUESTION
20	OF SEMANTICS. SO THAT'S THE ONLY THING BECAUSE
21	WHEN WE CALL IT A GRANT, IN MY MIND, JUST BEING A
22	SIMPLE PERSON AND NOT AN ATTORNEY, IF IT'S A GRANT
23	AND PROPOSITION 71 IS FAIRLY EXPLICIT ABOUT WHAT
24	HAPPENS WITH GRANTS, AND THERE'S A WHOLE BACKLOG OF
25	POLICY RELATING TO WHAT HAPPENS WITH GRANTS, THEN

1	IT'S HARD FOR ME TO BE SUPPORTIVE OF SOMETHING THAT,
2	EVEN WITH THE BEST INTENTIONS, DIVERTS REVENUE
3	STREAM FROM THE STATE, WHICH ALSO IS TRYING TO HELP
4	HUMAN HEALTH BY HAVING SUFFICIENT FUNDS FOR
5	MEDI-CAL, ALSO HAS OTHER VERY LAUDABLE GOALS LIKE
6	EDUCATION THAT ARE VERY MUCH PUBLIC GOODS AND CARE
7	FOR LOW-INCOME FOLKS AND FOR THE ELDERLY. IT'S JUST
8	HARD FOR ME TO TRY TO PUT MY MY PARTICULAR
9	INTEREST IN CIRM AHEAD OF THOSE OTHER INTERESTS AND
10	DECIDE UNILATERALLY TO REDIRECT THOSE FUNDS BACK TO
11	CIRM. THE LOAN PROGRAM WAS CLEARLY ENVISIONED IN
12	PROP 71 AS THEY MOVE FORWARD TO PROVIDE FOR
13	EVERGREENING OF CIRM. SO IT'S A SEMANTIC ISSUE WITH
14	REGARDS TO GRANTS AND LOANS, GRANTS AND LOANS THAT
15	PROVIDE AN EXTREME CHALLENGE.
16	MR. HARRISON: JEFF, MAYBE I CAN HELP YOU
17	BECAUSE I AT LEAST HAVE THOUGHT OF THIS DIFFERENTLY.
18	AND SOMETIMES THE NOMENCLATURE HAS KIND OF GOTTEN US
19	A LITTLE BIT TIED UP.
20	I THINK OF CIRM AS MAKING AWARDS. AND
21	THOSE AWARDS ARE GOVERNED BY A SET OF POLICIES. YOU
22	CAN ALMOST THINK OF IT AS EVERY AWARD UNDER 15-01
23	THROUGH 15-03 IS BY DEFAULT A LOAN BECAUSE THE
24	AWARDEE WOULD HAVE THE OPTION OF SAYING I'M GOING TO
25	MAKE THIS A LOAN, I'M GOING TO REPAY CIRM WITH A

	-
1	RATE OF RETURN, WHATEVER IT IS. BY MAKING THIS
2	DECISION TO TREAT IT AS A LOAN, I WILL CONTINUE TO
3	BE COVERED BY THE OTHER OBLIGATIONS, THE PRICING AND
4	THE MARCH-IN RIGHTS, BUT AS LONG AS I MAKE THAT
5	DECISION THE EARLIER OF SEVEN YEARS, AND WHETHER
6	IT'S THE DATE OF MARKET AUTHORIZATION BY THE FDA OR,
7	AS STEVE SUGGESTED, AN APPLICATION IS SUBMITTED FOR
8	MARKETING AUTHORIZATION, I THINK WE CAN PLAY WITH
9	THOSE DATES, BUT AN OUTER LIMIT ON IT. BUT AT THAT
10	POINT IN TIME, I'M TREATING THIS AS A LOAN. I REPAY
11	CIRM. CIRM GETS TO USE THOSE FUNDS PER PROP 71 TO
12	MAKE ADDITIONAL RESEARCH AWARDS.
13	MR. SHEEHY: MAYBE, AGAIN, MAYBE THIS IS
14	SEMANTICS. MAYBE WHEN WE TALK ABOUT THIS, WE CAN
15	STOP SAYING CONVERTING LOANS FROM AWARDS FROM
16	GRANTS TO LOANS.
17	MR. HARRISON: RIGHT.
18	MR. SHEEHY: THAT THEY HAVE THE OPTION TO
19	RECEIVE THEIR AWARD AS A GRANT OR LOAN OR SOME WAY
20	OF WHAT YOU'RE DESCRIBING IS WHAT I HAD
21	UNDERSTOOD THIS TO BE, WHICH I'M COMFORTABLE WITH.
22	WHAT I'M NOT COMFORTABLE WITH IS BUYING OUT
23	ROYALTIES TO THE STATE. THAT RAISES ISSUES WITH ME.
24	MR. HARRISON: SO MAYBE WE CAN REFRAME IT
25	A LITTLE BIT. AT LEAST I HAD IT IN MY MIND THAT
	27

	DARKISTERS REPORTING SERVICE
1	IT'S AN AWARD. IT'S AN AWARD, AND THE AWARDEE HAS
2	THE OPTION TO REPAY THAT AWARD. AND IF THE AWARDEE
3	DECIDES WITHIN A CERTAIN PERIOD OF TIME, SET THE
4	OUTER BOUNDARIES OF THAT
5	DR. MILLS: IF NOT, IT DEFAULTS TO A
6	GRANT.
7	MR. HARRISON: EXACTLY.
8	MR. SHEEHY: THAT'S SOMETHING SORRY,
9	STEVE. I THOUGHT WE MIGHT BE ABLE TO GET THERE
10	BECAUSE I THINK WE'RE ON SEMANTICS. THE SEMANTICS
11	WE'RE REALLY CHALLENGING. THIS LANGUAGE IS VERY
12	CHALLENGING HERE FOR ME. I APOLOGIZE.
13	CHAIRMAN JUELSGAARD: THAT'S ALL RIGHT.
14	MR. HARRISON: STEVE, IF IT'S OKAY FOR
15	JEFF AND THE REST OF THE MEMBERS, MAYBE I COULD TAKE
16	A CRACK AT REFORMULATING THE MEMO AND THE POWERPOINT
17	TO MAKE THAT SEMANTIC DISTINCTION MORE CLEAR. AND
18	IF YOU'D AUTHORIZE ME TO DO THAT AS PART OF THE
19	MOTION RECOMMENDING BOARD APPROVAL, THAT MIGHT BE
20	THE QUICKEST WAY TO MOVE FORWARD GIVEN THE FACT THAT
21	WE HAVE A BOARD MEETING THIS WEEK.
22	MR. SHEEHY: I'M COMFORTABLE WITH THAT AND
23	MAYBE THE OTHER MEMBERS ARE.
24	DR. BRYANT: I'D BE COMFORTABLE WITH THAT.
25	DR. DULIEGE: OF COURSE, ME TOO.
	28

1	MR. PANETTA: I AM TOO.
2	CHAIRMAN JUELSGAARD: ALL RIGHT. WELL,
3	THEN, CAN WE HAVE JAMES, WHY DON'T YOU FRAME THE
4	MOTION, AND THEN SOMEBODY CAN MAKE THE MOTION BASED
5	ON THE LANGUAGE YOU FRAMED.
6	MR. HARRISON: AS I UNDERSTAND IT, THE
7	MOTION IS TO RECOMMEND IN CONCEPT APPROVAL OF AN
8	OPTION TO CONVERT OR MAKE AN AWARD A LOAN WITH A
9	DEFAULT THAT IF THE GRANT WITHIN A SPECIFIED PERIOD
10	OF TIME AND TO DELEGATE TO THE CIRM TEAM THE TASK OF
11	WRITING THAT MORE CLEARLY AND SUCCINCTLY. AND
12	ASSUMING THE BOARD APPROVES IT, TO ASK THE BOARD TO
13	DELEGATE TO THE SUBCOMMITTEE THE RESPONSIBILITY TO
14	APPROVE A RATE OF RETURN BASED ON THE RECOMMENDATION
15	FROM THE CIRM TEAM.
16	CHAIRMAN JUELSGAARD: THANK YOU. THAT WAS
17	VERY CLEAR. WOULD ANYONE LIKE TO MAKE A MOTION TO
18	THAT EFFECT?
19	MR. SHEEHY: I WOULD MAKE THAT MOTION.
20	CHAIRMAN JUELSGAARD: THANK YOU, JEFF. IS
21	THERE A SECOND?
22	DR. DULIEGE: I SECOND.
23	CHAIRMAN JUELSGAARD: ALL RIGHT. GREAT.
24	ANY MORE DISCUSSION FROM MEMBERS OF THE
25	SUBCOMMITTEE? IF NOT, ANY DISCUSSION FROM MEMBERS
	29

1	OF THE PUBLIC WHO MIGHT BE ON THE LINE OR OTHERWISE
2	PRESENT? ALL RIGHT. IF THERE'S NO DISCUSSION ON
3	EITHER FRONT, THEN, MARIA, WOULD YOU CALL THE ROLL
4	PLEASE.
5	MS. BONNEVILLE: SURE. STEVE JUELSGAARD.
6	CHAIRMAN JUELSGAARD: YES.
7	MS. BONNEVILLE: JEFF SHEEHY.
8	MR. SHEEHY: YES.
9	MS. BONNEVILLE: OS STEWARD. JONATHAN
10	THOMAS.
11	CHAIRMAN THOMAS: YES.
12	MS. BONNEVILLE: JOE PANETTA.
13	MR. PANETTA: YES.
14	MS. BONNEVILLE: ANNE-MARIE DULIEGE.
15	DR. DULIEGE: YES.
16	MS. BONNEVILLE: SUE BRYANT.
17	DR. BRYANT: YES.
18	CHAIRMAN JUELSGAARD: WONDERFUL. IT'S
19	BEEN APPROVED. THANK YOU, EVERYONE.
20	THERE WASN'T ANYTHING ELSE ON THE AGENDA
21	AS IT WAS SENT OUT, BUT IS THERE ANYTHING ELSE THAT
22	ANY OTHER MEMBER OF THE SUBCOMMITTEE WOULD LIKE TO
23	RAISE AT THIS POINT, ANY OTHER ISSUES OR CONCERNS OR
24	ITEMS? ANY PUBLIC COMMENT OUTSIDE OF WHAT WE JUST
25	DID? WELL, IF NOT, THEN THIS MEETING STANDS
	30
	JU

```
1
      ADJOURNED.
 2
                 MS. BONNEVILLE: THANK YOU.
 3
                       (THE MEETING WAS THEN CONCLUDED.)
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                  31
```

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INTELLECTUAL PROPERTY AND INDUSTRY SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD MAY 18, 2015, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE 160 S. OLD SPRINGS ROAD SUITE 270 ANAHEIM, CALIFORNIA (714) 444-4100